Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 9:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 168 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Eosinophilic Oesophagitis Clear all
Terminated No phase listed Observational

Systems Biology of Gastrointestinal and Related Diseases

NCT05579444
View directory record Official record
Conditions
Ulcerative Colitis, Crohn Disease, Obesity, Colon Polyp, Eosinophilic Esophagitis, GERD, Gastro Esophageal Reflux, Barrett Esophagus, Esophageal Cancer, Gastritis, Gastric Ulcer, Duodenal Ulcer, Intestinal Metaplasia, Gastric Cancer, Lymphocytic Colitis, Microscopic Colitis, Celiac Sprue, IBS, Irritable Bowel Syndrome, SIBO, NAFLD, Gallstone Disease
Interventions
Not listed
Lead sponsor
Viome
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Bothell, Washington
Source: ClinicalTrials.gov public record
Updated Dec 15, 2023 · Synced Oct 11, 2026, 9:32 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Learn How Well Dupilumab Works in Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis and the Side Effects it May Have

NCT05831176
View directory record Official record
Conditions
Eosinophilic Gastritis (EoG), Eosinophilic Duodenitis (EoD), Eosinophilic Gastrointestinal Disease (EGID), Eosinophilic Gastroenteritis
Interventions
Dupilumab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
36
States / cities
Phoenix, Arizona • Apple Valley, California • La Jolla, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 11, 2026, 9:32 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis

NCT04753697
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
CC-93538, Placebo
Drug · Other
Lead sponsor
Celgene
Industry
Eligibility
12 Years to 75 Years
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
115
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Phoenix, Arizona + 97 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Oct 11, 2026, 9:32 PM EDT
Withdrawn No phase listed Observational

Eosinophilic Gastrointestinal Disorders Patient Registry

NCT01779154
View directory record Official record
Conditions
Eosinophilic Esophagitis, Eosinophilic Gastritis, Eosinophilic Enteritis, Eosinophilic Colitis
Interventions
Not listed
Lead sponsor
Arkansas Children's Hospital Research Institute
Other
Eligibility
Up to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jun 20, 2016 · Synced Oct 11, 2026, 9:32 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE-2)

NCT04281108
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
APT-1011, Placebo oral tablet, Esophagogastroduodenoscopy
Drug · Procedure
Lead sponsor
Ellodi Pharmaceuticals, LP
Industry
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
48
States / cities
Anniston, Alabama • Dothan, Alabama • Mobile, Alabama + 43 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2023 · Synced Oct 11, 2026, 9:32 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Imaging of the Esophagus Using a SECM Capsule

NCT03546660
View directory record Official record
Conditions
Eosinophilic Esophagitis, Barrett Esophagus
Interventions
SECM capsule
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
14 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Oct 11, 2026, 9:32 PM EDT
Terminated Not applicable Interventional

MRI to Assess Fibrosis in Eosinophilic Esophagitis Patients

NCT03446118
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
MRI to detect inflammation and fibrosis in subjects with EoE
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 28, 2022 · Synced Oct 11, 2026, 9:32 PM EDT
Completed No phase listed Observational

The Use of Fractionated Exhaled Nitric Oxide in the Diagnosis and Assessment of Disease Activity of Eosinophilic Esophagitis (Validation Phase)

NCT04941742
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Not listed
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
5 Years to 18 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 10, 2024 · Synced Oct 11, 2026, 9:32 PM EDT
Suspended No phase listed Observational Accepts healthy volunteers

Morphological Markers of Gastroesophageal Reflux Disease (GERD)

NCT01921686
View directory record Official record
Conditions
Eosinophilic Esophagitis, Gastroesophageal Reflux Disease
Interventions
Sample collection and Questionnaire
Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
8 Years to 18 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 11, 2026, 9:32 PM EDT
Recruiting No phase listed Observational

Study of Gastric Motility in Eosinophilic Gastritis

NCT05229432
View directory record Official record
Conditions
Eosinophilic Gastritis, Gastroparesis, Gastric Motility Disorder
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
18 Years to 59 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Chicago, Illinois • Bethesda, Maryland • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 11, 2026, 9:32 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Natural History and Genetics of Food Allergy and Related Conditions

NCT02504853
View directory record Official record
Conditions
Food Allergy, Loeys-Dietz Syndrome, Atopic Dermatitis, Eosinophilic Esophagitis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Day to 99 Years
Enrollment
1,800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 11, 2026, 9:32 PM EDT
Terminated Phase 1 Interventional

Sirolimus for Eosinophil-Associated Gastrointestinal Disorders

NCT01814059
View directory record Official record
Conditions
Eosinophilic Gastroenteritis, Eosinophilic Esophagitis
Interventions
sirolimus
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Oct 11, 2026, 9:32 PM EDT
Recruiting No phase listed Observational

A Registry for the Food Allergy Community

NCT04653324
View directory record Official record
Conditions
Food Hypersensitivity, Anaphylaxis, Eosinophilic Esophagitis, Food Sensitivity, Food Intolerance, Food Allergy in Infants
Interventions
Not listed
Lead sponsor
Food Allergy Research & Education
Other
Eligibility
Not listed
Enrollment
23,000 participants
Timeline
2017 – 2027
U.S. locations
1
States / cities
McLean, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 12, 2025 · Synced Oct 11, 2026, 9:32 PM EDT
Recruiting No phase listed Observational

Changes in Esophageal Distensibility With Proton Pump Inhibitors in Patients With Esophageal Eosinophilia: A Pilot Study

NCT03312686
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
endoflip
Diagnostic Test
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Oct 11, 2026, 9:32 PM EDT
Completed Phase 1Phase 2 Interventional

Anti-Interleukin-5 (IL-5) Study for Hypereosinophilic Syndrome

NCT00266565
View directory record Official record
Conditions
Hypereosinophilic Syndromes, Eosinophilic Gastroenteritis, Churg-Strauss Syndrome, Eosinophilic Esophagitis
Interventions
Mepolizumab
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 29, 2020 · Synced Oct 11, 2026, 9:32 PM EDT
Active, not recruiting No phase listed Observational

A U.S. Registry of Eosinophilic Esophagitis Pediatric, Adolescent and Adult Patients Treated With DUPIXENT® As Standard of Care

NCT06693531
View directory record Official record
Conditions
Eosinophilic Esophagitis (EoE)
Interventions
dupilumab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
1 Year and older
Enrollment
368 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
54
States / cities
Phoenix, Arizona • Sun City, Arizona • Little Rock, Arkansas + 43 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 11, 2026, 9:32 PM EDT
Completed Phase 2Phase 3 Interventional Results available

The Role Of Gastroesophageal Reflux Disease (GERD) in Eosinophilic Esophagitis

NCT00728481
View directory record Official record
Conditions
Eosinophilic Esophagitis, Gastroesophageal Reflux Disease, EE, GERD
Interventions
Esomeprazole, Budesonide
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 14, 2016 · Synced Oct 11, 2026, 9:32 PM EDT
Completed Not applicable Interventional

A Study of Baked Milk Tolerance to Treat Eosinophilic Esophagtis

NCT05606705
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Baked Milk
Dietary Supplement
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 9, 2026 · Synced Oct 11, 2026, 9:32 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Safety and Efficacy of Oral Etrasimod in Adult Participants With Eosinophilic Esophagitis

NCT04682639
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Etrasimod, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
221
States / cities
Birmingham, Alabama • Dothan, Alabama • Huntsville, Alabama + 85 more
Source: ClinicalTrials.gov public record
Updated May 6, 2024 · Synced Oct 11, 2026, 9:32 PM EDT
Completed Phase 1 Interventional

A Study Evaluating Potential Disease-Mediated Drug-Drug Interaction in Adult Participants With Active Eosinophilic Esophagitis Receiving Cendakimab

NCT05175352
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Cendakimab, CYP substrates
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
12
States / cities
Tucson, Arizona • Los Angeles, California • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2024 · Synced Oct 11, 2026, 9:32 PM EDT
Completed Phase 2 Interventional Results available

Study of Dupilumab in Adult Participants With Active Eosinophilic Esophagitis (EoE)

NCT02379052
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Dupilumab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
14
States / cities
Idaho Falls, Idaho • Chicago, Illinois • Urbana, Illinois + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2020 · Synced Oct 11, 2026, 9:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Comparing the Availability of AQ280 in the Body After Single Oral Doses of a Capsule Formulation Versus a Tablet for Oral Suspension Formulation

NCT07093008
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
AQ280 Capsule, AQ280 Tablet for Oral Suspension, Placebo Capsule, Placebo Tablet for Oral Suspension
Drug
Lead sponsor
AQILION AB
Industry
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 11, 2026, 9:32 PM EDT
Completed Phase 2 Interventional Results available

A Pilot Study of the Treatment of Eosinophilic Esophagitis With Omalizumab

NCT00123630
View directory record Official record
Conditions
Esophagitis
Interventions
omalizumab, Placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
12 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 20, 2016 · Synced Oct 11, 2026, 9:32 PM EDT
Completed Phase 4 Interventional Results available

Cycling of Topical Steroids for Treatment of EoE (Eosinopilic Esophagitis)

NCT05444543
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Fluticasone Propionate, Budesonide
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
4 Years to 18 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 7, 2024 · Synced Oct 11, 2026, 9:32 PM EDT